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Background: To assess the long-term cost-effectiveness of rosuvastatin therapy compared 
with generic simvastatin and generic atorvastatin in reducing the incidence of cardiovascular 
events and mortality in a Swedish population with Framingham risk $20%.
Methods: A probabilistic Monte Carlo simulation model based on data from JUPITER (the 
  Justification for the Use of statins in Prevention: an Intervention Trial Evaluating   Rosuvastatin) 
was used to estimate the long-term cost-effectiveness of rosuvastatin 20 mg daily versus 
simvastatin or atorvastatin 40 mg for the prevention of cardiovascular death and morbidity. 
The   three-stage model included cardiovascular event prevention simulating the 4 years of 
JUPITER, initial prevention beyond the trial, and subsequent cardiovascular event prevention. 
A Swedish health care payer perspective (direct costs only) was modeled for a lifetime horizon, 
with 2008/2009 as the costing period. Univariate and probabilistic sensitivity analyses were 
performed.
Results: The incremental cost per quality-adjusted life-year (QALY) gained with rosuvastatin 
20 mg over simvastatin or atorvastatin 40 mg ranged from SEK88,113 (rosuvastatin 20 mg 
versus simvastatin 40 mg; Framingham risk $30%; net avoidance of 34 events/1000 patients) 
to SEK497,542 (versus atorvastatin 40 mg: Framingham risk $20%; net avoidance of 
11 events/1000 patients) over a lifetime horizon. Probabilistic sensitivity analyses indicated 
that at a willingness-to-pay threshold of SEK500,000/QALY, rosuvastatin 20 mg would be 
cost-effective for approximately 75%–85% of simulations relative to atorvastatin or simvastatin 
40 mg. Sensitivity analyses indicated the findings to be robust.
Conclusion: Rosuvastatin 20 mg is cost-effective over a lifetime horizon compared with generic 
simvastatin or atorvastatin 40 mg in patients at high cardiovascular risk in Sweden.
Keywords: cardiovascular disease, cost-benefit analysis, cost-effectiveness, rosuvastatin, 
simvastatin, atorvastatin, generic, high risk
Introduction
The objective of cardiovascular disease management is now well established in 
the prevention of myocardial infarction, stroke, and cardiovascular death. Current 
treatment guidelines, including the US National Cholesterol Education Program 
Adult Treatment Panel III and updates1 and the European consensus guidelines,2,3 
recommend statin therapy for patients with established vascular disease, diabetes, 
and   hyperlipidemia. A 10% reduction in plasma levels of total cholesterol is followed 
by a 25% reduction in the incidence of coronary artery disease after 5 years, and 
a reduction in low-density lipoprotein cholesterol of 1 mmol/L is accompanied ClinicoEconomics and Outcomes Research 2012:4 submit your manuscript | www.dovepress.com
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by a 20%   reduction in coronary events.3–5 Current European 
guidelines suggest statin therapy for patients with a persistent 
SCORE (Systematic COronary Risk Evaluation) risk $5% 
despite lifestyle changes and dietary and exercise therapy.3 
SCORE is a more recently developed risk assessment 
system aimed at European clinical practice and is based on 
12 European cohort studies, allowing estimation of 10-year 
cardiovascular risk in ostensibly healthy persons.6 Swedish 
guidelines are also based on SCORE risk and recommend 
the use of a statin for at-risk patients who do not attain blood 
lipid goals (total cholesterol , 5.0 mmol/L and low-density 
lipoprotein cholesterol , 3.0 mmol/L, with more stringent 
targets for patients in certain very high-risk groups) with 
lifestyle, dietary, and exercise therapy.7
Despite these recommendations, approximately half of 
all myocardial infarctions and strokes are seen in persons 
with low-density lipoprotein cholesterol levels below the 
recommended thresholds for drug treatment.8 A recent clini-
cal trial, ie, JUPITER (Justification for the Use of statins in 
Prevention: an Intervention Trial Evaluating Rosuvastatin) 
demonstrated that rosuvastatin 20 mg daily significantly 
reduced the incidence of major cardiovascular events 
(CVEs) and all-cause mortality among individuals without 
hyperlipidemia but with elevated high-sensitivity C-reactive 
protein levels.9 These effects were similar in all subgroups, 
including patients at intermediate and high coronary disease 
risk (Framingham risk scores $10%).
The objective of the present study was to estimate 
the long-term cost-effectiveness of rosuvastatin 20 mg 
compared with atorvastatin 40 mg or simvastatin 40 mg 
in reducing major CVEs and mortality using a model 
  previously developed on the basis of the JUPITER results.10 
The JUPITER population included patients with a baseline 
high-sensitivity C-reactive protein level . 2 mg/L. For the 
current model, we used the relative risk reduction observed 
in JUPITER to predict CVEs for different populations with 
varying levels of baseline cardiovascular risk (estimated 
based on   Framingham risk score11), irrespective of baseline 
high-sensitivity C-reactive protein levels. The Framingham 
risk score is recommended in clinical guidelines as a tool 
to predict the absolute risk of coronary events in popula-
tions free of cardiovascular disease. It is calculated using 
gender, age, smoking status, total cholesterol, high-density 
lipoprotein, systolic blood pressure, and diabetes status. The 
  Framingham risk score indicates the risk level for a coronary 
heart disease event occurring within the following 10 years. 
The current analysis has a long-term (lifetime) time horizon 
and is based on patients with high baseline cardiovascular 
risk ($20% or $30% Framingham), which is in line with 
new European labeling recommendations. As indicated 
by current guidelines for cost-effectiveness analyses in 
Sweden, a long-term time horizon was utilized to capture 
the full costs and clinical effects of treatment for chronic 
conditions.12 Specifically, study time frames are required 
to cover the period when the main health effects and costs 
arise. Extrapolation beyond the time frame of clinical trials 
is therefore required, which is carried out via modeling. 
For the analyses presented here, clinically relevant dosages 
of rosuvastatin and two other statins were compared over 
lifetime and 20-year time horizons.
Materials and methods
The cost-effectiveness model used is based on the outcomes 
of JUPITER, and can analyze CVE reduction with rosuvasta-
tin 20 mg daily relative to no treatment,10 or can be used for 
active comparisons between differing dosages of rosuvastatin 
and other statins. Under the latter scenario, CVE reduction 
with the non-rosuvastatin comparators are approximated 
on the basis of their effect relative to rosuvastatin 20 mg in 
reducing the ratio of total serum cholesterol to HDL cho-
lesterol because the utility of this measure is established in 
the literature.13,14
The model incorporates the primary endpoints of   JUPITER, 
ie, fatal and nonfatal myocardial infarction, fatal and non-
fatal stroke, coronary arterial revascularization (  coronary 
artery bypass grafting [CABG] or percutaneous   transluminal 
coronary angioplasty/stent [PTCA]), unstable angina, or 
death from cardiovascular causes.   Noncardiovascular death 
and fatal and nonfatal venous thromboembolic events (both 
deep vein thrombosis and pulmonary embolism) are also 
included. The 4-year time frame of JUPITER is   simulated, 
with continuation beyond this to a stage simulating   initial 
prevention beyond the trial time frame (initial CVE 
prevention-post RCT [randomized controlled trial]), and 
finally to a subsequent event prevention stage, applied after 
a patient has an initial CVE (secondary CVE prevention, 
see Figure 1). A probabilistic first-order Monte Carlo micro-
simulation model estimates the long-term cost-effectiveness 
of treatment.
In this study, the simulation model assessed cost-
  effectiveness from a Swedish health systems payer perspec-
tive through the incorporation of direct medical costs for the 
years 2008/2009. The base case comparison was between 
rosuvastatin 20 mg and generic simvastatin 40 mg or generic 
atorvastatin 40 mg over a patient’s lifetime for persons in 
Sweden with a Framingham risk $20% or $30%.ClinicoEconomics and Outcomes Research 2012:4 submit your manuscript | www.dovepress.com
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Model structure
Simulations are performed with a cycle length of 3 months 
during the RCT stage and subsequently on a one-year cycle 
length until the patient’s death or attainment of age 100 years, 
or until the end of the specified model time frame. All 
patients start by entering the CVE prevention-RCT stage for 
up to 4 years. They then have an event probability (derived 
from the JUPITER data) on a 3-month basis from which 
they transfer to the subsequent prevention stage (initial 
CVE prevention-post RCT stage). The events are: nonfatal 
myocardial infarction, nonfatal stroke, unstable angina, 
CABG, or PTCA, which are followed by transition to the 
next stage of the model (secondary CVE prevention stage); 
cardiovascular death, noncardiovascular death or venous 
thromboembolic death, all of which occasion transition to 
the patient death stage; and 16 quarters (4 years) without a 
clinical endpoint, which is followed by retransition to the 
initial CVE prevention-post RCT stage. Nonfatal venous 
thromboembolism is possible in the CVE prevention-RCT 
stage, with accrual of associated costs, but does not force a 
transition because it is not considered to be a CVE. Patients 
without events stay in the initial prevention stage until the 
next cycle of the model. For patients who discontinue treat-
ment, the effect of treatment on event transition probabilities 
is phased out over 5 years (20% per year) as per the long-
term analysis of the West of Scotland Coronary Prevention 
Study.15 Treatment-persistent patients are assumed to have 
a 5% annual discontinuation probability, based on studies of 
statin persistence under usual care.16 Further details of the 
model have been published previously.10
Age-based CVE rates for the secondary CVE prevention 
stage were based on those reported in the National Institute 
for Health and Clinical Excellence Health   Technology 
Assessment 2007 report.17 Venous thromboembolism rates 
and relative risks were carried forward from the CVE 
  prevention-RCT to the post-RCT stages.   Noncardiovascular 
death rates were calculated in the same manner in the RCT 
and post-RCT stages of the model. Only one nonfatal CVD 
event per patient was allowed in each one-year cycle, 
although a single nonfatal venous thromboembolism was 
allowed with a nonfatal CVE.
Clinical events: primary and secondary 
CVE prevention
Events captured by the model were as already described. 
  Quarter by quarter probabilities of experiencing an initial 
event with rosuvastatin 20 mg were calculated by dividing 
the JUPITER trial-adjudicated quarterly event counts by the 
number of patients at risk at the beginning of a quarter for 
the first 4 years of the model (CVE prevention-RCT). These 
findings were used to construct survival curves for the trial 
period. Data were fitted to exponential curves with R2 values 
exceeding 0.97, from which were calculated constant time-
based event   probabilities. The relative risk of a primary CVE 
with rosuvastatin 20 mg treatment was then calculated from 
the ratio of treated and untreated event probabilities, and was 
determined to be 0.49 for patients at higher risk. This was used 
instead of the JUPITER trial relative risk of 0.56, as the con-
stant quarterly event probability calculation accounted for the 
shape of the curve (slope and height), providing an improved 
estimate for carrying forward over the long term, and the high 
R2 value of the fitted exponential curves provided the justifica-
tion for utilizing constant treatment relative risk values of a 
CVE during both the modeled trial and post-RCT stages.
JUPITER data were also used to calculate probability 
distributions of major CVEs. Arterial revascularization was 
Initial CVD
prevention
(RCT) 
Initial CVD 
prevention
(Post-RCT)
Patient
death* 
Subsequent
CVD
prevention   
*or end of
modelled
time frame 
1 year cycles  Max 4 years
¼ year cycles
(16 max)
 
 
1 year cycles 
Figure 1 Model structure overview. 
Abbreviations: CVD, cardiovascular disease; RCT, randomized controlled trial.ClinicoEconomics and Outcomes Research 2012:4 submit your manuscript | www.dovepress.com
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treated as a single event, assuming an 80:20 split between 
PTCA and CABG. The rate of venous thromboembolism 
was also derived from JUPITER.18 Venous thromboem-
bolic events were modeled as a weighted combination of 
deep vein thrombosis and pulmonary embolism events. 
  Noncardiovascular death rates were calculated using Swedish 
life tables.19 The annual probabilities of an initial event were 
adjusted and carried forward from the CVE prevention-RCT 
stage of the model to the initial CVE prevention-post RCT 
stage. The baseline probability was subsequently increased 
annually on the basis of Framingham 10-year risk age-
adjustment calculations,20 which yielded a model default 
age-based risk increase of approximately 5% per year. The 
relative risks of an event with rosuvastatin treatment, distribu-
tion of events, and venous thromboembolic event rates were 
all carried forward from the CVE prevention-RCT stage. 
Annual noncardiovascular death rates were calculated in the 
same manner as for the RCT stage.
Treatment continuation
During the CVE prevention-RCT stage of the model, the 
probability of a patient remaining on treatment declined 
linearly over the 4-year period to 75%, which corresponded 
to the discontinuation rate observed in the JUPITER trial. 
Accordingly, discontinuation did not affect effectiveness 
during this stage, because the impact of discontinuation is 
already reflected in the efficacy estimates from the clinical 
trial data. However, discontinuation did affect the estimated 
treatment costs by reflecting reduced drug use. For the 
  secondary CVE prevention stage of the model, treatment 
costs reflected decreased drug utilization, and the treatment 
relative risk was phased back to unity (relative risk = 1.0) 
over a five-year period for both the CVE prevention-post-
RCT and subsequent CVE prevention stages.
Clinical events: nonrosuvastatin  
20 mg comparators
CVE reduction effects were approximated on the basis of 
their effect on total cholesterol:HDL cholesterol ratios rela-
tive to rosuvastatin 20 mg. The algorithm used to calculate 
relative risks was based on the Framingham risk equation of 
Anderson et al.21 Default total cholesterol:HDL cholesterol 
reduction inputs were taken from Jones et al22 and from 
Schneck et al.23 Cardiovascular risk over 10 years was cal-
culated for an untreated population using the   Framingham 
risk equation, and was then repeated for the identical popu-
lations being treated with the various statins on the basis 
of total cholesterol:HDL cholesterol reductions. The event 
rates versus rosuvastatin 20 mg were calculated as ratios 
of the resulting 10-year cardiovascular risk.   Population 
characteristics defining modeled populations that are used 
as inputs in the Framingham risk equation are age, total 
  cholesterol, HDL cholesterol, systolic blood pressure, diabe-
tes, and   smoking. Default values corresponded to the overall 
  JUPITER population.9
Costs and cost-effectiveness
Costs, event counts, life-years gained, and quality-adjusted 
life-years (QALYs) were accumulated at each stage of the 
model for each cohort of patients (Figure 2). Costs included 
those associated with treatment (drugs, physician visits, and 
monitoring tests) and those related to events (hospitalization 
and physician visits associated with coronary events).
Prescription drug costs were obtained from Swedish 
public health sources, including the Swedish Association of 
Local Authorities and Regions,24 the Karolinska Institute,25 
and Swedish medical literature.26 Predicted future rosuvasta-
tin costs based on future availability of generic products were 
estimated by assuming a 95% reduction in price within one 
year of a generic becoming available. The specific event cost 
estimates used in the model are summarized in Table 1.
Incremental cost-effectiveness ratios (ICERs) were cal-
culated using the formula where effect is measured in either 
life-years or QALYs:
 
QALYI CER
TotalC osts TotalC osts
TotalE ffect To
(Tx) (NoT x)
(Tx)
=
−
− t talE ffect(NoT x)
Utilities
All simulated patients had an assigned initial baseline 
age-  adjusted utility value based on values reported in the 
literature,27 which was updated as the patient aged through 
the model. Utility weights for each model event were 
based on estimates reported in the literature28–30 (Table 2). 
  Multiplicative utility calculations were performed where 
patients had experienced more than one event and multiple 
disutility values were to be applied (the assumed “joint” 
utility value was the product of the individual utility values). 
Discounting with half-cycle correction of life-years, QALYs, 
and costs was performed with 3% annual discount rates.
sensitivity analyses
One-way sensitivity analyses were carried out by   decreasing 
(50%) or increasing (50% and 100%) secondary statin 
treatment costs, varying rosuvastatin discontinuation rates 
(to 50% over 4 years), varying proportions of patients ClinicoEconomics and Outcomes Research 2012:4 submit your manuscript | www.dovepress.com
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Simulate patient
through Tx arm    
Simulate patient
through no Tx arm    
Sum total
Tx arm costs, LYs
and QALYs
 
 
 
Accumulate
patient costs, LYs
and QALYs  
Accumulate
patient costs, LYs
and QALYs  
Sum total no
Tx arm costs, LYs
and QALYs
 
 
Calculate ICERs  
Assign patient
characteristics and
transitions  
Draw random
variates  
Enter
model  
Loop back to start the
next patient while
there are more 
patients to simulate  
Exit loop when all
patients have been
simulated 
Loop…   Loop… 
Figure 2 Model cohort simulation. 
Abbreviations: iCER, incremental cost effectiveness ratio; LYs, life-years; QALYs, quality-adjusted life-years; Tx, treatment.
Table 1 Direct medical cost estimates for cardiovascular events
Cardiovascular event direct costs  
(2008/2009 Swedish kronor)
Event year Subsequent years Source
nonFatal Mi 164,296.16 43,781.84 (25)
PTCA 69,700.00 0 (24)
CABG 167,000.00 0 (24)
Unstable angina 149,510.89 44,642.81 (25)
nonfatal stroke 163,205.00 57,304.00 (26)a
Cardiovascular death (secondary prevention) 17,762.00 0 (24)
noncardiovascular death Mexico ratios of cardiovascular death  
to noncardiovascular death cost
0
By cardiovascular death type (primary prevention)
Mi death 17,762.00 0 (24)
stroke death 17,762.00 0 (24)
Other cardiovascular death 17,762.00 0 (24)
Note: aCosts inflated to 2009 values.
Abbreviations: Mi, myocardial infarction; PTCA, percutaneous transluminal coronary angioplasty; CABG, coronary artery bypass graft.
starting secondary prevention therapy and subsequently 
  discontinuing, decreasing (50%) or increasing (50% or 
100%) event costs, altering (±50%) event disutilities, varying 
the discount rate between 0% and 5%, varying the primary 
CVE risk (±50%), and varying the primary prevention rela-
tive risk of CVE with rosuvastatin (±50%). The effect of 
reducing the time horizon of the model to 20 years was also 
examined, as were the effects of no future introduction of 
generic rosuvastatin and the adoption of the JUPITER relative 
risk of 0.56 (rather than 0.49) for a primary event ($20% 
Framingham risk only). The effect of increasing the dosage 
of rosuvastatin to 40 mg daily and atorvastatin to 80 mg daily ClinicoEconomics and Outcomes Research 2012:4 submit your manuscript | www.dovepress.com
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in patients at highest risk ($30%) was also investigated. 
Probabilistic sensitivity analyses were performed for event 
costs, event disutilities, and relative risk of events. For costs, 
log-normal distributions were used because costs tend to 
be skewed with a long tail at the high end. Full details are 
published elsewhere.10
Results
The ICERs for rosuvastatin are summarized in Table 3. For 
patients with a 10-year Framingham risk $20%, lifetime 
costs per QALY gained were SEK497,542 versus atorvas-
tatin 40 mg and SEK151,323 versus simvastatin 40 mg. 
  Corresponding costs per QALY in patients with $30% risk 
were SEK342,403 (versus atorvastatin) and SEK88,113 
  (versus simvastatin). Relative to atorvastatin 40 mg, 
with $20% and $30% risk, respectively, approximately 
11 and 14 CVEs were avoided over the projected lifetimes 
of 1000 patients, with 5.21 and 6.9 cardiovascular deaths, 
5.29 and 7.0 nonfatal myocardial infarctions, 2.89 and 3.16 
nonfatal strokes, and 1.87 and 2.32 PTCAs being avoided.
Relative to simvastatin 40 mg with $20% risk, approxi-
mately 26 CVEs were avoided with the use of rosuvastatin 
over the projected lifetimes of 1000 patients, with 11.95 
cardiovascular deaths, 13.48 nonfatal myocardial   infarctions, 
5.86 nonfatal strokes, and 4.72 PTCAs being avoided. 
  Corresponding figures for $30% risk were 34 CVEs, with 
15.71 cardiovascular deaths, 18.17 nonfatal myocardial 
infarctions, 7.02 nonfatal strokes, and 5.63 PTCAs avoided. 
For every 1000 modeled at-risk patients, the incremental 
direct medical cost of rosuvastatin over comparator statins 
at the dosages used in the model varied from approximately 
SEK11.5 million to SEK20 million, with an estimated 40.90 
to 129.50 QALYs gained over a lifetime (Table 3).
Sensitivity analyses were applied to assess the change in 
the ICER estimates across a wide range of statin drug costs, 
event costs, risks, discontinuation rates, discounting, and 
utility values. The results of the one-way sensitivity   analysis 
for the lifetime horizon in patients with a   Framingham 
risk $20% are summarized in the tornado diagrams in 
  Figure 3. In all scenarios, the variable with the greatest effect 
on estimated cost-effectiveness was the assumed treatment 
effectiveness of rosuvastatin in the initial prevention stage. 
In $20% risk patients in the atorvastatin comparison, an 
assumed 50% increase in rosuvastatin CVE relative risk (0.49 
to 0.735, ie, decreased effectiveness) approximately doubled 
the ICER to SEK1,016,394, whereas a 50% decrease (0.49 
to 0.245, ie, increased effectiveness) reduced the ICER to 
SEK327,523. A similar effect was seen in the simvastatin 
comparison, where a 50% increase in rosuvastatin CVE 
relative risk increased the ICER to SEK348,801, and a 50% 
decrease reduced the ICER to SEK80,777. For patients 
at $30% risk, a 50% increase in rosuvastatin CVE relative 
risk increased the ICERs to SEK702,023 versus atorvasta-
tin and to SEK231,574 versus simvastatin, whereas a 50% 
decrease in rosuvastatin CVE relative risk reduced the respec-
tive ICERs to SEK254,950 and SEK54,996 (data not shown). 
The primary CVE risk was the second most important influ-
ence on estimated cost effectiveness with both comparisons 
and in both risk groups. Some variation between groups was 
seen for the relative importance of the remaining factors, 
Table 2 Disutilities for CVD events
Event year Subsequent years
nonfatal Mi disutility28 0.24 0.24
PTCA disutility29 0.0175 0
CABG disutility29 0.037 0
Unstable angina disutility28 0.23 0
nonfatal stroke disutility30 0.37 0.37
CVD death disutility 0.5 1.0
non-CVD death disutility 0.5 1.0
Abbreviations:  CABG,  coronary  artery  bypass  graft;  CVD,  cardiovascular 
disease;  Mi,  Myocardial  infarction;  PTCA,  Percutaneous  transluminal  coronary 
angioplasty.
Table 3 Base case analysis for cost-effectiveness of rosuvastatin vs generic atorvastatin and simvastatin: lifetime horizon in patients 
with Framingham risk $20% or $30%. Results per 1000 patients with 95% generic price reduction assumption
Parameter Difference between RSV and comparator dose
$20% Risk $30% Risk
RSV20 vs SMV40 RSV20 vs ATV40 RSV20 vs SMV40 RSV20 vs ATV40
Total life-years gained (LYG) 97.32 41.61 132.00 58.18
Total quality-adjusted life-years (QALYs) gained 95.15 40.90 129.50 56.33
Total direct costs (sEK) 14,398,515 20,348,033 11,411,059 19,286,798
Cost per LYG (iCER) [sEK] 147,952 489,047 86,448 331,503
Cost per QALY gained (iCER) [sEK] 151,323 497,542 88,113 342,403
Abbreviations: ATV, atorvastatin; iCER, incremental cost-effectiveness ratio; LYG, life-year gained; QALY, quality adjusted life-year; sEK, swedish kronor; RsV, rosuvastatin; 
sMV, simvastatin.ClinicoEconomics and Outcomes Research 2012:4 submit your manuscript | www.dovepress.com
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Primary prevention – statin Tx annual discontinuation 497,542 505,745
327,523
342,608
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Discounting
Rosuvastatin cost per day
Event costs
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Secondary prevention – % initiate statin Tx
Secondary statin Tx cost per day
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A
Figure 3 (A) One-way sensitivity analysis of lifetime horizon for Framingham 20% risk population (JUPiTER population): rosuvastatin 20 mg versus atorvastatin 40 mg assuming 
a 95% generic price reduction from brand. (B) One-way sensitivity analysis of lifetime horizon for Framingham 20% risk population (JUPiTER population): rosuvastatin 20 mg 
versus simvastatin 40 mg assuming a 95% generic price reduction from brand. 
Abbreviations: CVD, cardiovascular disease; ICER, incremental cost-effectiveness ratio; SEK, Swedish kronor; Tx, treatment; JUPITER, the Justification for the Use of 
statins in Prevention: an intervention Trial Evaluating Rosuvastatin; RR, relative risk; QALY, quality adjusted life-year.
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B
with the applied discount rate, cost of CVEs, and daily cost 
of rosuvastatin being most influential across groups.
As shown in Table 4, shortening of the time horizon to 
20 years decreased the incremental cost-effectiveness of 
rosuvastatin relative to simvastatin and atorvastatin. At $20% 
risk, the effect of no future introduction of generic rosuvastatin 
was similar to that of restricting the time horizon to 20 years, 
whereas an increase in relative risk of a primary event (use 
of JUPITER relative risk of 0.56) was associated with slight 
reductions in ICERs relative to the base case comparisons 
(Table 4). Modeling of increased dosages in patients at highest 
risk ($30%) increased the ICER over the base case. The ICER 
of rosuvastatin 40 mg relative to atorvastatin 80 mg over a 
lifetime horizon was SEK493,003, ie, somewhat higher than 
the base case ICER of SEK342,403 for rosuvastatin 20 mg 
versus atorvastatin 40 mg in these high-risk patients.ClinicoEconomics and Outcomes Research 2012:4 submit your manuscript | www.dovepress.com
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Probabilistic sensitivity analysis was performed to assess 
the decision uncertainties in multiple model parameters. The 
cost-effectiveness acceptability curves generated (Figure 4) 
for different levels of willingness to pay for rosuvastatin 
20 mg relative to atorvastatin or simvastatin 40 mg in 
patients with a Framingham risk $20% indicate that, at 
a maximum willingness to pay threshold of SEK500,000 
per QALY gained, rosuvastatin therapy is cost-effective in 
74.4% and 85.3% of the model replications, respectively. At 
a   Framingham risk $30%, rosuvastatin is cost-effective for 
86.9% and 90.3% of model replications when compared with 
atorvastatin and simvastatin, respectively, at this willingness 
to pay threshold. At $20% risk, rosuvastatin is estimated to 
be cost-saving versus atorvastatin and simvastatin, respec-
tively, in 24.0% and 8.6% of model replications, and in 29.0% 
and 14.8% of replications at the $30% level.
Discussion
The comparisons carried out in the present study indicate 
that rosuvastatin 20 mg is likely to be cost-effective over 
generic atorvastatin or simvastatin 40 mg in terms of 
reducing cardiovascular mortality and morbidity among 
patients at moderate to high cardiovascular risk over a 
patient’s lifetime. The simulations modeled indicated overall 
ICERs (cost/QALY) associated with the use of rosuvastatin 
versus the other statins ranging from SEK88,113 (versus 
simvastatin 40 mg at $30% 10-year risk) to SEK497,542 
(versus atorvastatin 40 mg at $20% 10-year risk). The time 
horizon for this analysis extends beyond the anticipated 
market entry of generic rosuvastatin, and the current analysis 
therefore accounts for this as in previous work based on the 
JUPITER trial.10 Accounting for future generic drug costs 
is recognized as increasing the reliability of estimates of the 
true cost-effectiveness of a medical intervention.31–33
The cost-effectiveness of rosuvastatin was driven by 
cardiovascular events avoided. Deaths avoided tended to be 
counterbalanced to some extent by increases in noncardio-
vascular deaths with rosuvastatin relative to atorvastatin and 
simvastatin at the dosages examined, but this was likely to 
be intrinsically attributable to this increased avoidance of 
cardiovascular death. Patients who avoid premature death 
due to cardiovascular causes have an increased likelihood of 
dying from other noncardiovascular causes. This effect will 
increase in magnitude as the time horizon expands, and will 
be maximally expressed over a lifetime horizon.
Sensitivity analyses indicate that the incremental costs per 
QALY gained (or ICERs for short) were fairly robust with 
respect to time horizons of 20 years or longer. The probabilis-
tic sensitivity analysis for the lifetime horizon for a dosage of 
rosuvastatin 20 mg versus simvastatin or atorvastatin 40 mg 
indicated that, at a maximum willingness to pay a threshold 
of SEK500,000, rosuvastatin treatment would be acceptable 
in approximately 75%–85% of simulations.
The World Health Organization has suggested inter-
national cost-effectiveness threshold values of three times 
the gross domestic product per capita,34 and thresholds up 
to US$100,000 have been suggested.35,36 In Sweden, values 
equivalent to around US$100,000 (about €70,000) have been 
indicated on the basis of willingness to pay for prevention of 
road deaths.37 Based on the average exchange rate for USD 
to SEK in 2008/09 (7.123) this indicates equivalence to 
approximately SEK712,300 which would encompass all the 
quality-adjusted lifetime horizon estimates generated by the 
comparisons carried out here.
We note also that the model as applied in the present 
study focused on at-risk patient populations with Framing-
ham scores $20% or $30%. The model used the relative 
risk of 0.49 for the at-risk population rather than the JUPI-
TER relative risk of 0.56. This value was used because it 
gave the best representation of the curve for cardiac event 
risk and was the best estimate to carry forward over the 
long-term model. However, previously published data have 
shown this relative risk to yield similar results to the relative 
risk of 0.56 when used for the at-risk population.10 The use 
of patient populations with high Framingham risk scores 
reflects the need for more aggressive statin   treatments in 
Table 4 Cost-effectiveness of rosuvastatin (RsV) vs atorvastatin (ATV) and simvastatin (sMV): effect of alteration of time horizon, no 
future introduction of generic rosuvastatin, and increase in cardiac event relative risk
Parameter Drug comparison
$20% Risk $30% Risk
RSV20 vs SMV40 RSV20 vs ATV40 RSV20 vs SMV40 RSV20 vs ATV40
20-year time horizon 198,415 640,708 112,545 423,036
no introduction of generic rosuvastatin 216,924 650,169 133,359 446,428
Cardiac event relative risk 0.56 132,257 445,792 73,141 298,318
Abbreviations: ATV, atorvastatin; iCER, incremental cost-effectiveness ratio; RsV, rosuvastatin; sEK, swedish kronor; sMV, simvastatin.ClinicoEconomics and Outcomes Research 2012:4 submit your manuscript | www.dovepress.com
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Figure 4 (A) Willingness to pay-cost/QALY iCER with a lifetime horizon for Framingham 20% risk population (JUPiTER population) rosuvastatin 20 mg versus atorvastatin 
40 mg, assuming a generic 95% price reduction from brand. (B) Willingness to pay-cost/QALY iCER with a lifetime horizon for Framingham 20% risk population (JUPiTER 
population) rosuvastatin 20 mg versus simvastatin 40 mg, generic 95% price reduction from brand. 
Abbreviations: QALY, quality adjusted life year; ICER, incremental cost-effectiveness ratio; SEK, Swedish kronor; JUPITER, the Justification for the Use of statins in 
Prevention: an intervention Trial Evaluating Rosuvastatin.
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higher-risk populations to address their higher unmet medi-
cal need,1 because elevated cardiovascular risk represents 
an economic burden to health care providers. To explore 
further the use of more aggressive therapy, we also modeled 
rosuvastatin 40 mg versus atorvastatin 80 mg over a lifetime 
in patients at highest risk who might require higher daily 
dosages to achieve their lipid goals. Although there was an 
increase in the ICER of rosuvastatin under this scenario, 
which was driven by an increase in cost associated with drug 
therapy, the ICER generated was still below SEK500,000 
and within the limits of what would be considered cost-
effective in Sweden. The effect of no future introduction of 
generic rosuvastatin and restriction of the time horizon to 
20 years also yielded ICERs for rosuvastatin that remained 
within the boundaries of what is likely to be considered 
cost-effective.ClinicoEconomics and Outcomes Research 2012:4 submit your manuscript | www.dovepress.com
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The results of the present study build on the findings of the 
previous cost-effectiveness comparison of rosuvastatin and 
placebo in patients at moderate to high risk,10 and suggest that 
this agent is likely to be cost-effective relative to atorvastatin 
or simvastatin, as well as relative to no statin treatment. Our 
scenario accounts for the likely introduction within the pro-
jected time horizons of generic   rosuvastatin, which increases 
confidence in the cost estimates. The   methodological strength 
of the comparisons is improved by the use of the ratio between 
total and HDL cholesterol levels in serum as a calibration 
  factor, given that total cholesterol:HDL cholesterol is reported 
to be a reliable predictor of cardiovascular risk.13,14
As with all cost-effectiveness models, ours is subject to 
limitations that merit consideration. Various input param-
eters were estimated and derived from the literature or 
other publicly available data sources, which by their nature, 
introduce inherent uncertainty. As is standard practice, we 
attempted to assess robustness of results against parameter 
estimate uncertainties by performing sensitivity analyses. 
We used Swedish life tables to estimate cardiovascular and 
noncardiovascular mortality, which is relevant, given differ-
ences in treatment patterns in different countries (eg, criteria 
for coronary interventional procedures).38–41 JUPITER used 
a placebo comparison group, and the first published use of 
the present model simulated initial prevention based upon 
a placebo comparison. Both analyses to date have been car-
ried out from a direct health care payer’s perspective, and 
indirect costs covering lost wages or productivity have not 
been included. Indirect costs would be of interest and would 
reflect increased incidences of coronary events leading, for 
example, to lost work time in patients treated with placebo 
because of increased incidences of coronary events. They 
would also show up societal effects of differences in efficacy 
and adverse event profiles between statins. Thus, future work 
would benefit from inclusion of indirect (societal) costs, 
especially given the lifetime perspective of the simulations.
Rosuvastatin 20 mg daily is therefore likely to be a 
cost-effective intervention for the long-term management 
of coronary risk when compared with either placebo (ie, no 
treatment)10 or with atorvastatin or simvastatin 40 mg daily 
in patients with elevated risk of coronary disease. The current 
inter-statin estimates as presented here are limited to direct 
medical costs in Sweden, and future research should expand 
estimates to include other countries and payer perspectives, 
most notably societal (indirect) costs over the lifetime hori-
zon, which would only add to the benefits of rosuvastatin 
(and therefore make rosuvastatin an even more cost-effective 
alternative.
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